Clinical Trial Update: Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis [Phase 3]

View source ↗

Summary

Phase 3 trial of MAX-002 suppository for mild to moderate ulcerative proctitis was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis
• Ulcerative Proctitis

Drugs mentioned

• MAX-002 suppository

Snippet

Sponsor: Forest Laboratories | Conditions: Proctitis, Ulcerative | Phase 3 | Status: TERMINATED | Results posted: 2019-08-28